Photo: The Financial Express
DRDO Invites EoI To Transfer Tech Of 2-DG Drug For Bulk Production
The DRDO created 2-Deoxy-D-Glucose (2-DG) has solicited Expression of Interest for the technology to be licensed to Indian pharmaceutical businesses for production. The drug was developed by a DRDO lab- the Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr. Reddy Laboratories. Helping COVID patients for a faster recovery, the drug reduces dependency on medical oxygen. Notably, a higher number of patients treated with… read-more
Tags: DRDO, Dr Reddy's, Covid-19, Indian Pharma
Courtesy: The Indian Express
Photo: The News Minute
DCGI Nods Emergency Use Of Zydus Cadila's 'Virafin' For Moderate COVID-19
The Drugs Controller General of India on April 23 approved the emergency use of Zydus Cadila's Pegylated Interferon alpha-2b (PegIFN), ‘Virafin' to treat moderately infected COVID patients. Reportedly, Zydus claims that 91.5% of patients administered with this drug have shown fast recovery while requiring less oxygen for treatment. Interestingly, they also tested negative on RT-PCR test by day 7. India recorded 3.32 lakh fresh COVID-19 cases… read-more
Tags: Virafin, DCGI, Covid-19, drug, Indian Pharma
Courtesy: Times Now news
Photo: News18 Hindi
India to Have 10,500 Janaushadhi Kendras by 2025, Says Sadananda Gowda
Ministry of Chemicals and Fertilisers on September 17 revealed that it plans to have at least 10,500 'Pradhan Mantri Bharatiya Janaushadhi Kendras (PMBJK)' by 2025. Union Minister Sadananda Gowda said 10,500 PMBJKs would ensure that the service reaches every corner of the country. The PMBJK initiative aims at providing quality medicines at affordable rates. According to the ministry,… read-more
Tags: India, Indian Pharma, medicine, Central Government
Courtesy: The Economic Times
Photo: CGTN.com
Kochi-based Pharma Gets Approval to Start Phase-2 Trials for COVID-19 Drug
Central Licensing Authority, under the Central Drugs Standard Control Organization, has granted approval to Kochi-based pharma, PNB Vesper to begin phase-2 trials of a COVID-19 drug. The drug, 'PNB001', which is a new chemical entity (one that contains molecules which have never been approved by USFDA), is the first-of-its-kind to start phase-2 trials. According to… read-more
Tags: Covid-19, Coronavirus, coronavirus treatment, Kochi, Indian Pharma
Courtesy: The Economic Times
Photo: The Print
Favipiravir Tablet to be Available in 400mg for COVID-19 Treatment
BDR Pharmaceuticals has planned to launch 400mg Favipiravir tablets after approval from DCGI. It will cost Rs 990 for a strip of 10 'Favipiravir 400 mg' tablets. The Favipiravir tablets are currently available in 200 mg and are being used to treat COVID-19 patients with 'mild-symptoms'. "Introducing a higher… read-more
Tags: Indian Pharma, Coronavirus, Covid-19, Favipiravir
Courtesy: The Economic Times
Photo: The Financial Express
Andhra Government to Set up Bulk Drug Park; Signs MoU with CSIR-IICT
The Andhra Pradesh Industrial Infrastructure Corporation (APIIC) on September 03 signed a MoU with the CSIR-IICT to set up a Bulk Drug Park (BDP) in the state. As a knowledge partner, CSIR-IICT will provide technical inputs for preparing the blueprint of BDP. Earlier, the Centre had announced to extend grants-in-aid to states for development of three bulk drug and four medical device… read-more
Tags: Indian Pharma, Andhra Pradesh, Union government, APIs
Courtesy: The New Indian Express
Photo: Washington Times
Companies Conduct Antibody Drug Tests to Combat COVID-19
Pharmaceutical companies are piercing through the idea of the infusion of a drug that delivers the antibodies to fight the coronavirus, without the immune system being trained to produce it. As an immediate effective alternate for the vaccine to combat the coronavirus, a lot of studies are being conducted in this regard. Reportedly, the dosage can be effective for a month or more to people at high risk of infection.
Tags: Covid-19, drug, Covid-19 Test, Indian Pharma
Courtesy: Hindustan Times
